Protocols
5 protocol(s) meet the specified criteria
Drug: RITUXAN
Protocol No.TitleStatus
CALGB50403A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggresive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell LymphomaOpen (affiliates only)
CALGB50803A Phase II Trial of Lenalidomide (Revlimid™, CC-5013)(NSC #703813, IND #70116) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin’s Lymphoma (NHL) Open (affiliates only)
LCCC1503A Phase I/Ib Study of Alisertib plus R-EPOCH for Treatment of Myc-Positive Aggressive B-Cell LymphomasOpen
S1001A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) Open (affiliates only)
SGN19A-003A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplantOpen